2022
DOI: 10.1016/j.ad.2022.04.003
|View full text |Cite
|
Sign up to set email alerts
|

[Translated article] Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 36 publications
0
1
0
Order By: Relevance
“…Radiotherapy and electrochemotherapy are used as an alternative therapy to surgery in complex areas such as the face, in elderly patients with comorbidities or in recurrent BCC 9,10 . Hedgehog inhibitors (vismodegib and sonidegib) have shown good results in locally advanced and metastatic BCC 11 , 12 . Recently, cemiplimab (programmed death receptor 1 inhibitor) was approved as a second treatment option in resistant cases 13 .…”
Section: Introductionmentioning
confidence: 99%
“…Radiotherapy and electrochemotherapy are used as an alternative therapy to surgery in complex areas such as the face, in elderly patients with comorbidities or in recurrent BCC 9,10 . Hedgehog inhibitors (vismodegib and sonidegib) have shown good results in locally advanced and metastatic BCC 11 , 12 . Recently, cemiplimab (programmed death receptor 1 inhibitor) was approved as a second treatment option in resistant cases 13 .…”
Section: Introductionmentioning
confidence: 99%